CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,366 enrolled
Drug / intervention
Teriparatide +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01709110
NCT01709110Phase 4Completed
CompareCT.gov

Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures

Eli Lilly and Company·interventional·Posted Oct 17, 2012·Updated Sep 23, 2019

In Brief

A Phase 4 clinical trial evaluating Teriparatide, Risedronate, and 3 other interventions for Postmenopausal Osteoporosis. Completed, enrolled 1,366 participants across 103 sites in 15 countries.

Detailed Summary

The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopausal Osteoporosis
CountriesArgentina, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Greece, Hungary, Italy, Poland, Puerto Rico, Spain, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 17, 2012
Enrollment StartOct 1, 2012
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.7 years ago

Interventions

Teriparatidedrug

Administered SC

Risedronatedrug

Administered orally

Placebodrug

Teriparatide arm placebo administered orally. Risedronate arm placebo administered SC.

Calciumdrug

Administered orally

Vitamin Ddrug

Administered orally